CYCLODEXTRIN-ENHANCED MICRONEEDLE SYSTEMS FOR PACLITAXEL DELIVERY: A REVIEW OF CURRENT ADVANCES AND FUTURE PROSPECTS

Abstract

Delivering drugs safely and effectively still challenges today’s medicine, especially with high-potency anticancer agents like Paclitaxel. Standard recognized formulations confront pharmacokinetic ceilings caused by Paclitaxel’s low aqueous solubility and severe side effects triggered by conventional excipients, so researchers are rapidly diversifying the delivery toolbox. This review evaluates the independent advantages cyclodextrins and microneedle arrays hold as next-generation delivery platforms. Cyclodextrins are still the mainstay of polymer-based delivery systems as they encapsulate and increase the relativistic pharmacokinetics of almost any soluble and lipophilic therapeutics. In addition, solid-dissolved or fumed Powders microneedle arrays form arrays of micron-sized reservoirs that are painlessly penetrated to the skin's Visco-elastic barrier once these are applied to the skin. Both drug-loaded systems, collaborating, generate a pharmacodynamically robust subcutaneous depot that shelters Paclitaxel from excipient toxicity and dramatically narrows its tissue-accumulation zone. Research synthesizing cyclodextrins, microneedle formulations, and Paclitaxel, though at the feasibility stage, is seeding pre-clinical uses and borrowed formulations, so provisionally analogous combined studies still furnish a sound proof of concept. Credible pre-existing library and concept studies of cyclodextrin- or polymer-embedded, Paclitaxel-loaded microneedle templates validate the combined concept.